Canaccord Genuity Reiterates a 'Sell' on Seattle Genetics (SGEN); ADC Technology Drug Candidate Falls Flat
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Sell' on Seattle Genetics (NASDAQ: SGEN), PT $10.
Canaccord analyst says, "We maintain our SELL thesis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "We maintain our SELL thesis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
